NCT06001151 (ACHELOUS) is a Phase 2 clinical trial of Cadonilimab in Carcinoma, Non-Small-Cell Lung, sponsored by Qian Chu.

Who is sponsoring NCT06001151?

NCT06001151 is sponsored by Qian Chu.

What drugs are being tested in NCT06001151?

Interventions in NCT06001151: Cadonilimab, Pemetrexed, Carboplatin.

What condition does NCT06001151 study?

NCT06001151 studies Carcinoma, Non-Small-Cell Lung.

Is NCT06001151 still recruiting?

NCT06001151 is currently recruiting now. Last updated 21 August 2023.

Last reviewed 2023-08-21 · How we verify

NCT06001151: ACHELOUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Recruiting now Phase 2 Last updated 21 August 2023

What this trial tests

Phase 2 trial testing Cadonilimab in Carcinoma, Non-Small-Cell Lung in 49 participants. Currently enrolling.

Timeline

7 August 2023

Primary endpoint
31 August 2025

31 August 2027

Quick facts

Lead sponsor	Qian Chu
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	49
Start date	7 August 2023
Primary completion	31 August 2025
Estimated completion	31 August 2027
Sites	1 location across China

Drugs / interventions tested

Cadonilimab — full drug profile →
Pemetrexed — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

Qian Chu — full company profile →

Who can join

Adults 18 to 75, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cadonilimab

Trials testing the same drug.

NCT07446257 — THIO and Cadonilimab in Resectable Hepatocellular Carcinoma · EARLY_PHASE1 · not yet recruiting
NCT07243951 — Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therap · Phase 2 · not yet recruiting
NCT06913218 — A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically R · Phase 1 · not yet recruiting
NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting
NCT06789848 — Ligufalimab and Cadonilimab in Advanced Liver Cancers · Phase 2 · recruiting

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other Qian Chu trials

Trials by the same sponsor.

NCT07055581 — Durvalumab as Consolidation for Patients LS-SCLC · Phase 2 · recruiting
NCT07131670 — Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Report · recruiting
NCT04888429 — Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma · Phase 2 · recruiting
NCT04871997 — A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06001151 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qian Chu
Last refreshed: 21 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06001151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing